Development
NP Life Sciences Health Industry Group Inc.
NPLS
$0.0539
-$0.0962-64.09%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -83.66% | 257.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.66% | 257.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -83.66% | 257.00% | |||
| SG&A Expenses | 54.06% | 23.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 54.06% | 23.96% | |||
| Operating Income | -152.38% | 5,850.00% | |||
| Income Before Tax | -152.95% | 5,833.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -152.95% | 5,833.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -152.95% | 5,833.33% | |||
| EBIT | -152.38% | 5,850.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -152.94% | -- | |||
| Normalized Basic EPS | -150.00% | -- | |||
| EPS Diluted | -152.94% | -- | |||
| Normalized Diluted EPS | -150.00% | -- | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||